Measles crosses 2,000 — and three new studies change the fall vaccine math

This is the June 8, 2026 edition, covering June 1–8.

Flu is at its summer floor. The real news this week comes from three directions: measles hit a grim milestone faster than anyone expected, a pair of policy proceedings ticked forward without resolution, and three research papers landed with direct implications for how US families should approach fall vaccination. Here's what matters and what to do with it.

Measles: 2,030 cases in five months — and a Texas childcare outbreak explains how

The US confirmed its 2,030th measles case for 2026 as of June 4, spread across 40 jurisdictions and tied to 30 active outbreaks. 1 That milestone arrived in roughly five months — last year's total of 2,288 cases for the entire year wasn't reached until late December. 2

The headline number tells you the pace. A new MMWR (Morbidity and Mortality Weekly Report, CDC's primary disease surveillance publication) report published June 4 tells you the mechanism. 3

In March 2025, a single unvaccinated 3-year-old arrived at a Lubbock, Texas childcare facility with early measles symptoms. The facility had 287 enrolled children, 48 staff, and a documented MMR (measles-mumps-rubella) vaccination rate of 96% among children 12 months and older — well above the level most public health guidelines treat as adequately protected. By the end of the outbreak: 8 confirmed cases (7 children, 1 adult grandfather), one child hospitalized with pneumonia, and a response involving 10 surrounding counties. 3

Three things made the 96% coverage insufficient here:

39 infants under 12 months were enrolled — 13.6% of children at the facility. Babies this young are too young for MMR and have no vaccine protection. Three of the eight cases were infants in this group.
10 children held vaccine exemptions. Three of them got measles — a 30% infection rate among unvaccinated children versus near-zero among vaccinated ones.
Lubbock County's broader MMR rate was only 82% for 1–3 year olds and 90% for 4–5 year olds. 3 The 96% at the facility was an island inside a weaker community. Once measles got in, there was nowhere for it to go except to the unprotected edges.

Texas kindergarten conscience exemptions have been climbing: 2.14% of kindergarteners in 2020–21, rising to 3.95% statewide by 2024–25, and 4.49% in Lubbock County specifically. 3 A community where nearly 1 in 20 kindergarteners is unvaccinated cannot sustain the 95% vaccination coverage threshold that blocks measles from spreading.

The MMWR authors noted a counterintuitive containment decision: Lubbock Public Health chose not to exclude infants under 6 months from the facility entirely. Their reasoning — forcing families home might push them toward other childcare settings and spread measles further. Instead, LPH separated those infants into a dedicated room with their own staff. 3

CDC global measles travel map showing air routes connecting continents with plane icons — Measles moves with travelers — nearly every US outbreak in 2026 traces back to an international exposure. 1

The vaccination picture nationally: 92% of 2026 US measles cases occurred in people who were unvaccinated or had unknown vaccination status. 1 Kindergarten MMR coverage nationally has slipped from 95.2% in 2019–20 to 92.5% in 2024–25, leaving roughly 286,000 kindergarteners unprotected below the herd immunity threshold at any given time. 1

One piece of relatively good news: the Utah outbreak — the country's largest, at 486 cases — added only 9 new cases over the past three weeks and appears to be slowing. 2 A new case appeared in Erie County, New York — the first there since 2018 — traced to international travel. 2

What this means for your family:

If your child attends childcare and is 6–11 months old, talk to your pediatrician. The standard schedule calls for the first MMR dose at 12–15 months — but CDC guidance allows the vaccine as early as 6 months in outbreak situations. Your pediatrician can assess local risk.
If you're pregnant or have an infant under 6 months, your own immunity affects your baby. The MMR is safe to receive before pregnancy if you're not already immune — a simple antibody titer blood test can confirm your status.
If you have school-age children in a county with high exemption rates: check whether your school district's posted exemption rate is above 5%. That's the threshold where a single case can become a cluster.

Flu surveillance: a quiet Week 21 with one wrinkle

CDC's Week 21 FluView, published June 5 (data through May 30), is exactly what the off-season should look like. Flu-like illness at 1.6% of outpatient visits, unchanged from Week 20, with all 55 jurisdictions at minimal activity. 4 Lab positivity ticked down to 1.4% (427 of 30,574 samples tested). 4

Five more pediatric deaths were reported, bringing the final 2025–26 season toll to 179 confirmed child flu deaths — up from 174 at Week 20. 4 All five were late-reported cases that actually occurred between December 2025 and May 2026. Multi-week reporting delays are normal in the surveillance system.

One wrinkle: National Center for Health Statistics (NCHS) mortality surveillance data were absent from this week's report — the first time that's happened since the off-season streamlined reporting format began. 4 Whether this is a one-week technical glitch will be clear when next week's report publishes.

On H5 bird flu: no new human infections. The US total remains 71 confirmed human cases since February 2024, with 1 death. 5 Nebraska dairy cattle tested positive for H5N1 for the first time on record (confirmed by TAHC/USDA on June 2), and Utah's Cache County also confirmed a positive herd on June 1. 6 Florida issued an emergency rule requiring negative H5N1 tests for dairy shipped across state lines. CDC's human surveillance systems show no unusual flu activity in people. 5

Scientist in protective lab gear examining samples under a microscope — representing flu and H5N1 laboratory surveillance — Flu and H5N1 surveillance depends on labs like this one — clinical and public health labs collectively tested over 30,000 samples in Week 21 alone. 4

Policy: ACIP still frozen, Moderna's advisory hearing in 10 days

ACIP (Advisory Committee on Immunization Practices, the CDC panel that votes on the US vaccine schedule) remains paralyzed. The June 24–26 meeting is on CDC's official calendar, but the March 16 federal court injunction barring 13 of the committee's 15 Kennedy appointees from serving also prevents any formal votes. 7 8 HHS re-established ACIP's governing charter in May, removing explicit references to mRNA vaccine reviews and replacing specific expertise requirements (toxicologist, data scientist) with "a balanced range of scientific, clinical, and public health expertise," but that change has no effect on the injunction. 8 The District Court issued scheduling and discovery orders on June 1; HHS's appeal to the First Circuit has no hearing date set. 9

The practical consequence: ACIP votes trigger zero-cost vaccine coverage under Section 2713 of the Affordable Care Act (ACA). With the committee unable to vote, there is ongoing uncertainty about whether that automatic no-cost protection will apply to new vaccine recommendations in fall 2026. AHIP (the trade group for health insurers) says its member plans will continue first-dollar coverage for all existing ACIP-recommended vaccines through end of 2027, regardless of the political situation. 10 That commitment covers existing recommendations — not any new ones the committee can't vote on.

Moderna's MFLUSIVA (mRNA-1010) VRBPAC hearing is June 18. VRBPAC (Vaccines and Related Biological Products Advisory Committee) is the FDA's independent expert panel that reviews vaccine applications before the FDA makes a final approval decision. The hearing will evaluate Moderna's mRNA-based flu vaccine for adults 50 and older. Briefing documents are expected around June 16–17 but had not posted as of June 8. 11 The FDA's formal review deadline is August 5, 2026 (the PDUFA date — Prescription Drug User Fee Act target action date, the FDA's self-imposed decision deadline). If the advisory committee votes favorably and the FDA acts on schedule, this vaccine could reach pharmacies in time for fall 2026.

Two state legislative notes:

Illinois SB 3487 passed both chambers and awaits Governor Pritzker's signature, with an approximate July 20 deadline. 12 If signed, hospitals would be required to identify and offer flu vaccines to admitted patients 18 and older (previously only required for patients 50+) and pneumococcal vaccines to patients 50 and older (previously 65+).
Iowa SF 304, signed May 19, removes minors' ability to consent to HPV (human papillomavirus) and hepatitis B vaccines without parental permission. That law takes effect July 1, 2026 — three weeks away. 8 If you have a teenager in Iowa who still needs either vaccine series, act before July 1.

Three research findings with direct fall vaccine implications

A young girl receives a vaccination at a clinic, with a cheerful expression after getting a band-aid — Photo: CDC / Pexels 13

FluMist shedding may last longer than previously known

A study presented at the ASM Microbe 2026 conference (Los Angeles, June 1–5) found that healthy adults who received FluMist — formally called live attenuated influenza vaccine (LAIV), a vaccine that contains a weakened live flu virus delivered via nasal spray — sometimes tested positive for the vaccine virus in nasal samples for up to 7 days post-vaccination, longer than prior guidance documented. 14 Shedding patterns varied significantly between individuals.

Important caveat: the full dataset — sample size, exact shedding rates, proportion involving replication-competent (potentially transmissible) virus — was not publicly available at press time because the conference paper is paywalled.

The implication for families is nonetheless concrete. The injectable flu shot contains no live virus and has zero shedding concern. For households that include an immunocompromised member — someone on chemotherapy, a transplant recipient, or anyone on immunosuppressive medication — CDC guidance already recommends the injectable over FluMist. This new data extends the recommended caution period and reinforces that guidance. If anyone in your household has an uncertain or weakened immune status, choose an injectable flu vaccine this fall.

Adults born 1957–1985 may get less H1N1 protection from flu shots

A Journal of Infectious Diseases study published June 8 analyzed data from the US Flu Vaccine Effectiveness Network's 2023–24 season. 15 Adults born between 1957 and 1985 (roughly ages 41 to 69 today) showed the lowest vaccine effectiveness against H1N1 influenza of any birth cohort studied. More than 60% of infected individuals in this group had hemagglutination inhibition (HI) antibody titers at or below 10 during acute illness, a level indicating minimal protective immunity. 15

The researchers' explanation centers on immune imprinting: the first influenza virus a child is exposed to shapes the immune system's flu response for decades afterward. People born in this window were likely first exposed to USSR/77-like H1N1 strains that circulated from the late 1970s onward — strains quite different from the H1N1 that has dominated since 2009. The immune system, trained on the old version, responds less robustly to the current one even after vaccination.

The study's practical conclusion: improving vaccine immunogenicity (the strength of the immune response a vaccine triggers) could help override this birth cohort effect. 15 For people in this age range, that's one more argument for higher-potency flu formulations. If you're 41–64 and have been getting standard-dose flu shots, ask your pharmacist or doctor about adjuvanted (Fluad) or high-dose (Fluzone High-Dose) options this fall.

Shingrix can be given the same day as flu and COVID shots

A Phase 4 randomized controlled trial published in the Journal of Infection on June 4 enrolled 967 adults aged 50 and older across 13 UK sites. 16 The trial tested whether the recombinant shingles vaccine Shingrix (RZV — recombinant zoster vaccine) could be given on the same day as either an adjuvanted flu shot or an mRNA COVID-19 vaccine, without reducing the immune response to any of the three vaccines.

All co-administration combinations met the trial's non-inferiority standard — meaning the combined-administration groups produced antibody responses that were statistically equivalent to getting each vaccine alone. Safety was acceptable: the proportion of participants reporting Grade 3 (severe but temporary) systemic reactions in the 7 days after vaccination reached up to 3.3% in the Shingrix + COVID group, versus 1.2% for COVID alone, but all reactions resolved without lasting effects. 16

The practical upshot: if you or a parent are 50+ and behind on Shingrix (the vaccine requires two doses, 2–6 months apart), you don't need a separate medical visit. You can get it the same day as your fall flu shot or COVID booster. That simplifies logistics considerably for anyone who finds extra appointments hard to schedule.

What to do right now

Check your child's MMR vaccination record this week. If your child is in daycare or school and not fully vaccinated — 2 doses for children 4 and older, 1 dose for children 12–47 months — call your pediatrician. With 2,030 measles cases circulating across 40 jurisdictions, the exposure risk is real.
If you're 41–69 and typically get a standard-dose flu shot each fall, ask this year about adjuvanted or high-dose options. Fluad and Fluzone High-Dose are already available at most pharmacies — the new birth cohort study suggests standard-dose shots may leave many people in this age group with less H1N1 protection than assumed.
If anyone in your household is immunocompromised, skip FluMist this fall and choose an injectable flu vaccine. The new ASM Microbe 2026 data extends the shedding caution period; the injectable is the safe default.
If you or a parent is 50+ and needs Shingrix, you can schedule it the same visit as your fall flu shot and COVID booster. No spacing required.
Iowa families with teenagers: the window for minors to get HPV or hepatitis B vaccines without parental consent closes July 1, 2026 — three weeks away. If your teenager hasn't completed either series, act now.
Watch June 18: the FDA's expert advisory panel meets to evaluate Moderna's mRNA-1010 flu vaccine for adults 50+. Briefing documents post around June 16. If the vote is favorable and FDA approves by August 5, pharmacies may have it available in time for fall.

Flu surveillance data from CDC FluView Week 21 (ending May 30, 2026). Measles data from CDC case tracker (June 4, 2026 update) and MMWR Vol. 75, No. 21. H5N1 cattle update from Texas Animal Health Commission (June 2, 2026). Policy reporting from CIDRAP/Unbiased Science (May 28), Georgetown litigation tracker (June 1), and Immunize.org IZ Express Issue 1877 (June 2). Research findings from Journal of Infectious Diseases (PMID 42253097), Journal of Infection (PMID 42248304), and IDSE/ASM Microbe 2026 conference report.

AI-generated cover image.